Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended Follow-up of Fianlimab Plus Cemiplimab in Melanoma
NCT06848088Phase 2Enrolling by invitation
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Apr 2025
- Primary completion
- Oct 2029
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 2
01
Overview
Phase 2, open-label trial of fianlimab and cemiplimab in melanoma (2 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Overall Survival at 4 years. Started Apr 2025; status: enrolling by invitation.
02
Drugs
fianlimabcemiplimab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT06848088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06848088.